INNOVENT BIO (01801) announced its annual results for the period ending December 31, 2025. Total revenue reached 13.0415 billion yuan, representing a year-on-year increase of 38.4%. Since the launch of its first product in 2019, the company has rapidly expanded its commercial scale, demonstrating its forward-looking strategic planning and efficient commercialization capabilities. The company achieved its first full-year profit, with net profit under IFRS reaching 813.6 million yuan. The year 2025 marked a milestone in INNOVENT BIO's development history. The company achieved historic breakthroughs in three dimensions: business scale, profitability, and global innovation, establishing itself as a leading biopharmaceutical company with both high growth potential and high certainty. For the year ended December 31, 2025, and up to the date of this announcement, the company successfully upgraded its "dual-engine" strategy, maintaining a leading position in oncology while its comprehensive product portfolio contributed to new growth. With all profitability metrics turning positive, the company has officially entered a new era of sustainable profitability. Concurrently, three innovative assets have advanced to or are nearing global Phase III clinical development. Through multiple significant strategic collaborations, the company is accelerating the realization of global pipeline value, laying a solid foundation for its strategic goal of becoming a world-class biopharmaceutical company by 2030. The company's product portfolio has expanded to 18 marketed products, 12 of which have been included in China's National Reimbursement Drug List (NRDL). In oncology, the company successfully launched several innovative products, including OYI XIN®, DABOLE®, JIEPALI®, and DABOXIN®, further consolidating its leading position in China's oncology treatment field. Within its comprehensive product line, the company successfully expanded its commercial footprint, establishing new growth pillars. Products such as XINERMEI®, XINBILE®, and XINBIMIN® have become key new growth drivers. Additionally, XINMEIYUE®, a cornerstone product in the autoimmune disease area, received market approval at the end of 2025. Furthermore, the updated 2025 NRDL, effective January 1, 2026, included a new indication for DABOSHU® and added XINBIMIN®, OYI XIN®, DABOTE®, DABOLE®, RUITO®, and JIEPALI® for the first time.